TY - JOUR
T1 - Modulating the microbiome to improve therapeutic response in cancer
AU - McQuade, Jennifer L.
AU - Daniel, Carrie R.
AU - Helmink, Beth A.
AU - Wargo, Jennifer A.
N1 - Funding Information:
JLM is supported by the Melanoma Research Alliance, the Elkins Foundation, an American Society of Clinical Oncology and Conquer Cancer Foundation Career Development Award, an MD Anderson Cancer Center (MDACC) Melanoma SPORE Developmental Research Program Award, and the MD Anderson Physician Scientist Program and acknowledges the Transdisciplinary Research in Energetics and Cancer Research Training Workshop R25CA203650 and the MDACC Center for Energy Balance in Cancer Prevention and Survivorship. CRD is supported by the American Cancer Society (RSG-17-049-01-NEC), Melanoma Research Alliance, and National Cancer Institute (CCSG 5P30 CA016672-37 to MD Anderson). JAW is supported by the US National Institutes of Health (1 R01 CA219896-01A1), US–Israel Binational Science Foundation (201332), Kennedy Memorial Foundation (0727030), the Melanoma Research Alliance (4022024), American Association for Cancer Research Stand Up To Cancer (SU2C-AACR-IRG-19-17), US Department of Defense (W81XWH-16-1-0121), MDACC Multidisciplinary Research Program Grant, Andrew Sabin Family Fellows Program, and MDACC's Melanoma Moon Shots Program. JAW is a member of the Parker Institute for Cancer Immunotherapy at MDACC.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/2
Y1 - 2019/2
N2 - Although novel therapies, including immunotherapy, have dramatically improved outcomes for many patients with cancer, overall outcomes are heterogeneous and existing biomarkers do not reliably predict response. To date, predictors of response to cancer therapy have largely focused on tumour-intrinsic features; however, there is growing evidence that other host factors (eg, host genomics and the microbiome) can substantially affect therapeutic response. The microbiome, which refers to microbiota within a host and their collective genomes, is becoming increasingly recognised for its influence on host immunity, as well as therapeutic responses to cancer treatment. Importantly, microbiota can be modified via several different strategies, affording new angles in cancer treatment to improve outcomes. In this Review, we examine the evidence on the role of the microbiome in cancer and therapeutic response, factors that influence and shape host microbiota, strategies to modulate the microbiome, and present key unanswered questions to be addressed in ongoing and future research.
AB - Although novel therapies, including immunotherapy, have dramatically improved outcomes for many patients with cancer, overall outcomes are heterogeneous and existing biomarkers do not reliably predict response. To date, predictors of response to cancer therapy have largely focused on tumour-intrinsic features; however, there is growing evidence that other host factors (eg, host genomics and the microbiome) can substantially affect therapeutic response. The microbiome, which refers to microbiota within a host and their collective genomes, is becoming increasingly recognised for its influence on host immunity, as well as therapeutic responses to cancer treatment. Importantly, microbiota can be modified via several different strategies, affording new angles in cancer treatment to improve outcomes. In this Review, we examine the evidence on the role of the microbiome in cancer and therapeutic response, factors that influence and shape host microbiota, strategies to modulate the microbiome, and present key unanswered questions to be addressed in ongoing and future research.
UR - http://www.scopus.com/inward/record.url?scp=85060874585&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(18)30952-5
DO - 10.1016/S1470-2045(18)30952-5
M3 - Review article
C2 - 30712808
AN - SCOPUS:85060874585
VL - 20
SP - e77-e91
JO - The Lancet Oncology
JF - The Lancet Oncology
SN - 1470-2045
IS - 2
ER -